LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

Search

Innoviva Inc

Closed

SectorHealthcare

19.46 0.05

Overview

Share price change

24h

Current

Min

19.46

Max

19.62

Key metrics

By Trading Economics

Income

-67M

-47M

Sales

-3.2M

89M

P/E

Sector Avg

51.694

53.54

EPS

-0.743

Profit margin

-52.559

Employees

127

EBITDA

-63M

-27M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+182.2% upside

Dividends

By Dow Jones

Next Earnings

29 lip 2025

Market Stats

By TradingEconomics

Market Cap

15M

1.2B

Previous open

19.41

Previous close

19.46

News Sentiment

By Acuity

50%

50%

174 / 381 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Strong Bullish Evidence

Innoviva Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

30 maj 2025, 23:51 UTC

Acquisitions, Mergers, Takeovers

Trump Raises Steel Tariffs, Saying U.S. Steel Will Remain U.S.-Controlled -- Update

30 maj 2025, 21:30 UTC

Top News

Stocks Shrug Off Trade War to Post Best Month Since 2023 -- WSJ

30 maj 2025, 21:15 UTC

Top News

The Score: E.l.f. Beauty, Tesla, Nvidia, and More Stocks That Defined the Week -- WSJ

30 maj 2025, 20:50 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Health Care Roundup: Market Talk

30 maj 2025, 20:44 UTC

Acquisitions, Mergers, Takeovers

Bill Ackman Is Killing It. A New ETF Will Track His Investments. -- Barrons.com

30 maj 2025, 20:24 UTC

Top News

Major U.S. Stock Indexes Finish About Flat; U.S.-China Trade Friction Renews -- WSJ

30 maj 2025, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

30 maj 2025, 19:44 UTC

Market Talk

Gold Breaks 4-Month Winning Streak -- Market Talk

30 maj 2025, 19:38 UTC

Market Talk

Companies Delay or Cancel $14B In Clean-Energy Investments -- Market Talk

30 maj 2025, 19:29 UTC

Earnings
Acquisitions, Mergers, Takeovers

NRG Energy and UnitedHealth Are the S&P 500's Best and Worst for May. Here's Why. -- Barrons.com

30 maj 2025, 19:14 UTC

Market Talk

Oil Settles Lower Ahead of OPEC+ Output Decision -- Market Talk

30 maj 2025, 19:05 UTC

Market Talk

U.S. Natural Gas Futures Fall Awaiting Hotter Weather -- Market Talk

30 maj 2025, 18:51 UTC

Market Talk

Canada's Retaliatory Tariffs Help Fuel Sizable Rise in Tax Revenue -- Market Talk

30 maj 2025, 18:37 UTC

Market Talk
Earnings

Costco Well Positioned for Sustainable Growth, UBS Says -- Market Talk

30 maj 2025, 18:04 UTC

Top News

S&P 500 Falls After More Trump-China Friction -- WSJ

30 maj 2025, 17:47 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

30 maj 2025, 17:47 UTC

Market Talk

Time for BoC Gov. Macklem to Cut Rates, Desjardins Says -- Market Talk

30 maj 2025, 17:40 UTC

Acquisitions, Mergers, Takeovers

Trump Is Praising His U.S. Steel Deal. No One Is Sure What It Means -- WSJ

30 maj 2025, 17:38 UTC

Market Talk

U.S: Oil Rig Count Falls for Fifth Straight Week -- Market Talk

30 maj 2025, 17:31 UTC

Market Talk

Costco Well Positioned to Gain Share Amid Tariffs, Baird Says -- Market Talk

30 maj 2025, 17:14 UTC

Top News

American Consumers Are Still Gloomy on the Economy -- 3rd Update

30 maj 2025, 16:31 UTC

Earnings

Ulta Beauty Stock Is Rising. Earnings Strength Was More Than Cosmetic. -- Barrons.com

30 maj 2025, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

30 maj 2025, 16:20 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Health Care Roundup: Market Talk

30 maj 2025, 16:16 UTC

Top News

S&P 500 Falls After Trump Hits Out at China -- WSJ

30 maj 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

30 maj 2025, 16:14 UTC

Top News

HSBC Retreats From Banking Smaller U.S. Businesses -- WSJ

30 maj 2025, 16:12 UTC

Market Talk

Base Metal Prices Slide on Stronger Dollar But Copper Shortage Fears Remain -- Market Talk

30 maj 2025, 16:02 UTC

Market Talk

Latest Twists in U.S. Tariff Saga Being Digested by Commodity Markets -- Market Talk

30 maj 2025, 15:31 UTC

Top News

Judge Considers Curbs for Google in AI Arms Race -- Update

Peer Comparison

Price change

Innoviva Inc Forecast

Price Target

By TipRanks

182.2% upside

12 Months Forecast

Average 55 USD  182.2%

High 55 USD

Low 55 USD

Based on 1 Wall Street analysts offering 12 month price targets forInnoviva Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

1 ratings

1

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

18.57 / 18.75Support & Resistance

Short Term

Strong Bullish Evidence

Intermediate Term

Weak Bullish Evidence

Long Term

Neutral Evidence

Sentiment

By Acuity

174 / 381 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Innoviva Inc

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.